US · HIMS · MEDICAL - EQUIPMENT & SERVICES
Hims & Hers Health, Inc. (HIMS) intrinsic value and stock valuation
$14.60as of 2026-11-21 · Mkt cap 7.06B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Hims & Hers Health, Inc. DCF and intrinsic value
InvestorsCraft values HIMS with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from HIMS’s statements →
Hims & Hers Health, Inc. Graham Number
Graham Number: $5.56d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Moderna, Inc. (MRNA) $195.00
- Baxter International Inc. (BAX) $25.39
- Revvity, Inc. (RVTY) $145.22
- Penumbra, Inc. (PEN) $319.12
- Align Technology, Inc. (ALGN) $155.17
- BioMarin Pharmaceutical Inc. (BMRN) $60.41
- Bio-Techne Corporation (TECH) $72.67
- The Ensign Group, Inc. (ENSG) $176.32
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.35B | $1.48B | $872M | $526.9M | $271.9M |
| Operating income | $105.6M | $61.9M | -$-29.45M | -$-68.7M | -$-115.04M |
| Net income | $128.4M | $126M | -$-23.55M | -$-65.68M | -$-107.66M |
| EPSd | $497.1K | $532.2K | -$-112.5K | -$-321.14K | -$-576.4K |
| Operating cash flow | $300M | $251.1M | $73.5M | -$-26.53M | -$-34.41M |
| Capital expenditure | -$-226.04M | -$-52.75M | -$-26.49M | -$-7.25M | -$-5.01M |
| Free cash flow | $74M | $198.3M | $47M | -$-33.78M | -$-39.42M |
| Total assets | $2.15B | $707.5M | $441.2M | $366.3M | $420.6M |
| Total debt | $1.12B | $11.4M | $9.95M | $5.31M | $5.48M |
| Net debt | $892M | -$-209.24M | -$-86.72M | -$-41.47M | -$-66.3M |
| Total equity | $540.9M | $476.7M | $344M | $311.7M | $334.6M |
| Cash and short-term investments | $577.5M | $300.3M | $221M | $179.6M | $247.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.35B | $1.48B | $872M | $526.9M | $271.9M |
| Cost of revenue | $614.3M | $303.4M | $157.1M | $118.2M | $67.4M |
| Gross profit | $1.73B | $1.17B | $715M | $408.7M | $204.5M |
| Research and development expenses | $149.3M | $78.8M | $48.2M | $29.2M | $22.4M |
| Selling, general and administrative expenses | $1.19B | $846.6M | $576.3M | $370.8M | $249.6M |
| Other expenses | $286.4M | $185.8M | $119.9M | $77.4M | $47.6M |
| Operating expenses | $1.63B | $1.11B | $744.4M | $477.4M | $319.5M |
| Cost and expenses | $2.24B | $1.41B | $901.5M | $595.6M | $386.9M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $54.5M | $17.1M | $9.52M | $7.47M | $4.08M |
| Ebitda | $178.4M | $88.8M | -$-12.06M | -$-58.23M | -$-106.72M |
| Operating income | $105.6M | $61.9M | -$-29.45M | -$-68.7M | -$-115.04M |
| Total other income/expenses, net | $18.3M | $9.81M | $7.88M | $2.99M | $4.25M |
| Income before tax | $123.9M | $71.7M | -$-21.57M | -$-65.71M | -$-110.8M |
| Income tax expense | -$-4.44M | -$-54.33M | $1.98M | -$-30K | -$-3.14M |
| Net income | $128.4M | $126M | -$-23.55M | -$-65.68M | -$-107.66M |
| Weighted average shares outstanding | $225M | $215.9M | $209.3M | $204.5M | $186.8M |
| Weighted average diluted shares outstanding | $258.2M | $236.8M | $209.3M | $204.5M | $186.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $577.5M | $300.3M | $221M | $179.6M | $247.3M |
| Net receivables | $32.2M | $6.08M | $6.75M | $3.23M | $3.58M |
| Inventory | $115.7M | $64.4M | $22.5M | $21.6M | $13.6M |
| Total current assets | $767.6M | $395.8M | $265.1M | $216.6M | $269.9M |
| Property, plant and equipment, net | $449M | $93M | $45.7M | $16.1M | $5.11M |
| Goodwill and intangible assets | $474.4M | $156.1M | $129.5M | $132.7M | $136.8M |
| Long-term investments | $351.3M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $1.39B | $311.7M | $176.1M | $149.8M | $150.7M |
| Total assets | $2.15B | $707.5M | $441.2M | $366.3M | $420.6M |
| Accounts payable | $143.3M | $91.2M | $43.1M | $32.4M | $19.6M |
| Short-term debt | $4.84M | $1.89M | $1.28M | $1.66M | $1.36M |
| Deferred revenue | $127.2M | $75.3M | $7.73M | $1.47M | $3.19M |
| Total current liabilities | $404.4M | $221.4M | $88.5M | $47.9M | $79.2M |
| Long-term debt | $1.12B | $9.46M | $8.67M | $3.65M | $4.12M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $1.21B | $9.46M | $8.69M | $6.66M | $6.75M |
| Capital lease obligations | $148M | $11.4M | $9.95M | $5.31M | $5.48M |
| Total liabilities | $1.61B | $230.8M | $97.2M | $54.6M | $86M |
| Common stock | $20K | $20K | $20K | $20K | $20K |
| Retained earnings | -$-113.77M | -$-242.14M | -$-368.18M | -$-344.63M | -$-278.95M |
| Accumulated other comprehensive income (loss) | $2.29M | -$-320K | -$-120K | -$-280K | -$-140K |
| Total equity | $540.9M | $476.7M | $344M | $311.7M | $334.6M |
| Total investments | $700.1M | $79.7M | $124.3M | $132.9M | $175.5M |
| Total debt | $1.12B | $11.4M | $9.95M | $5.31M | $5.48M |
| Net debt | $892M | -$-209.24M | -$-86.72M | -$-41.47M | -$-66.3M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $128.4M | $126M | -$-23.55M | -$-65.68M | -$-107.66M |
| Depreciation and amortization | $54.5M | $17.1M | $9.52M | $7.47M | $4.08M |
| Stock-based compensation | $135.2M | $92.3M | $66.1M | $42.8M | $67.2M |
| Change in working capital | -$-29.16M | $78.6M | $20.8M | -$-14.2M | $3.46M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | -$-13.72M | -$-41.61M | -$-900K | -$-8M | -$-9.63M |
| Accounts payable | $30.3M | $43.7M | $7.32M | $12.7M | $9.85M |
| Net cash provided by operating activities | $300M | $251.1M | $73.5M | -$-26.53M | -$-34.41M |
| Investments in property, plant and equipment | -$-226.04M | -$-41.66M | -$-17.22M | -$-2.71M | -$-830K |
| Acquisitions, net | -$-145.23M | -$-15.4M | $0.00 | -$-460K | -$-46.47M |
| Net cash used for investing activities | -$-1.02B | -$-19.05M | -$-12.11M | $34.7M | -$-156.27M |
| Common stock issued | $17.5M | $0.00 | $0.00 | $0.00 | $272.7M |
| Common stock repurchased | -$-89.96M | -$-83.04M | -$-2M | $0.00 | -$-22.03M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $729.6M | -$-107.84M | -$-11.47M | -$-33.13M | $235M |
| Net change in cash | $8.03M | $123.9M | $49.9M | -$-25.01M | $44.3M |
| Cash at end of period | $228.6M | $221.4M | $97.5M | $47.6M | $72.6M |
| Operating cash flow | $300M | $251.1M | $73.5M | -$-26.53M | -$-34.41M |
| Capital expenditure | -$-226.04M | -$-52.75M | -$-26.49M | -$-7.25M | -$-5.01M |
| Free cash flow | $74M | $198.3M | $47M | -$-33.78M | -$-39.42M |
Line items
Line items
Line items
About Hims & Hers Health, Inc.
Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.
- CEO
- Andrew Dudum
- Employees
- 2.44K
- Beta
- 2.34
Explore
Frequently asked questions
What is the intrinsic value of Hims & Hers Health, Inc. (HIMS)?
Hims & Hers Health, Inc. (HIMS) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is HIMS undervalued?
HIMS trades at a price of $14.60 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.